Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benzamide Derivatives for Clozapine-induced Hypersalivation
NCT00534573Phase 3Completed
- Sponsor
- Be'er Sheva Mental Health Center
- Start
- Nov 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amisulpride, moclobemide and tiapride in clozapine-induced hypersalivation (CIS) (2 arms), sponsored by Be'er Sheva Mental Health Center. Primary endpoints: Hypersalivation assessed by Clinical Global Impression (CGI) patient's self assessment and Hypersalivation assessed by Nocturnal Hypersalivation Rating Scale (NHRS). Started Nov 2008; status: completed.
02
Drugs
amisulpridemoclobemidetiapride
03
Conditions
clozapine-induced hypersalivation (CIS)
Beyond the preview
Go deeper on NCT00534573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00534573.